Takeda Pharmaceutical Co Ltd: Skyline Study in Dravet Syndrome Narrowly Missed Its Primary Endpoint
武田製藥公司:Skyline針對Dravet綜合症的研究未能達到主要終點
Takeda Pharmaceutical Co Ltd: Skyline Study in Dravet Syndrome Narrowly Missed Its Primary Endpoint
武田製藥公司:Skyline針對Dravet綜合症的研究未能達到主要終點
譯文內容由第三人軟體翻譯。